Oxidative and nitrosative stress in pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide

Stephen Matthew Black, Jeffrey R. Fineman

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

An increasing number of studies implicate oxidative stress in the development of endothelial dysfunction and the pathogenesis of cardiovascular disease. Further, this oxidative stress has been shown to be associated with alterations in both the endothelin-1 (ET-1) and nitric oxide (NO) signaling pathways such that bioavailable NO is decreased and ET-1 signaling is potentiated. However, recent data, from our groups and others, have shown that oxidative stress, ET-1, and NO are co-regulated in a complex fashion that appears to be dependent on the cellular levels of each species. Thus, when ROS levels are transiently elevated, NO signaling is potentiated through transcriptional, post-transcriptional, and post-translational mechanisms. However, in pediatric pulmonary hypertensive disorders, when reactive oxygen species (ROS) increases are sustained by ET-1 mediated activation of smooth muscle cell ETA subtype receptors, NOS gene expression and NO signaling are reduced. Further, increases in oxidative stress can stimulate both the expression of the ET-1 gene and the secretion of the ET-1 peptide. Finally, the addition of exogenous NO, and increasingly utilized therapy for pulmonary hypertension, can also lead to increases ROS generation via the activation of ROS generating enzymes and through the induction of mitochondrial dysfunction. Thus, this manuscript will review the available data regarding the interaction of oxidative and nitrosative stress, endothelial dysfunction, and its role in the pathophysiology of pediatric pulmonary hypertension. In addition, we will suggest avenues of both basic and clinical research that will be important to develop novel pulmonary hypertension treatment and prevention strategies, and resolve some of the remaining clinical issues regarding the use of NO augmentation.

Original languageEnglish (US)
Pages (from-to)308-316
Number of pages9
JournalVascular Pharmacology
Volume45
Issue number5
DOIs
StatePublished - Nov 1 2006

Fingerprint

Endothelin-1
Pulmonary Hypertension
Nitric Oxide
Oxidative Stress
Pediatrics
Reactive Oxygen Species
Enzyme Induction
Smooth Muscle Myocytes
Cardiovascular Diseases
Gene Expression
Lung
Peptides
Research
Genes

Keywords

  • Cell signaling
  • Gene expression
  • Nitrosylation
  • Pulmonary hypertension
  • Reactive oxygen species

ASJC Scopus subject areas

  • Physiology
  • Molecular Medicine
  • Pharmacology

Cite this

Oxidative and nitrosative stress in pediatric pulmonary hypertension : Roles of endothelin-1 and nitric oxide. / Black, Stephen Matthew; Fineman, Jeffrey R.

In: Vascular Pharmacology, Vol. 45, No. 5, 01.11.2006, p. 308-316.

Research output: Contribution to journalArticle

Black, Stephen Matthew ; Fineman, Jeffrey R. / Oxidative and nitrosative stress in pediatric pulmonary hypertension : Roles of endothelin-1 and nitric oxide. In: Vascular Pharmacology. 2006 ; Vol. 45, No. 5. pp. 308-316.
@article{63177d801bce4240bb200e203dfee14b,
title = "Oxidative and nitrosative stress in pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide",
abstract = "An increasing number of studies implicate oxidative stress in the development of endothelial dysfunction and the pathogenesis of cardiovascular disease. Further, this oxidative stress has been shown to be associated with alterations in both the endothelin-1 (ET-1) and nitric oxide (NO) signaling pathways such that bioavailable NO is decreased and ET-1 signaling is potentiated. However, recent data, from our groups and others, have shown that oxidative stress, ET-1, and NO are co-regulated in a complex fashion that appears to be dependent on the cellular levels of each species. Thus, when ROS levels are transiently elevated, NO signaling is potentiated through transcriptional, post-transcriptional, and post-translational mechanisms. However, in pediatric pulmonary hypertensive disorders, when reactive oxygen species (ROS) increases are sustained by ET-1 mediated activation of smooth muscle cell ETA subtype receptors, NOS gene expression and NO signaling are reduced. Further, increases in oxidative stress can stimulate both the expression of the ET-1 gene and the secretion of the ET-1 peptide. Finally, the addition of exogenous NO, and increasingly utilized therapy for pulmonary hypertension, can also lead to increases ROS generation via the activation of ROS generating enzymes and through the induction of mitochondrial dysfunction. Thus, this manuscript will review the available data regarding the interaction of oxidative and nitrosative stress, endothelial dysfunction, and its role in the pathophysiology of pediatric pulmonary hypertension. In addition, we will suggest avenues of both basic and clinical research that will be important to develop novel pulmonary hypertension treatment and prevention strategies, and resolve some of the remaining clinical issues regarding the use of NO augmentation.",
keywords = "Cell signaling, Gene expression, Nitrosylation, Pulmonary hypertension, Reactive oxygen species",
author = "Black, {Stephen Matthew} and Fineman, {Jeffrey R.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.vph.2006.08.005",
language = "English (US)",
volume = "45",
pages = "308--316",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Oxidative and nitrosative stress in pediatric pulmonary hypertension

T2 - Roles of endothelin-1 and nitric oxide

AU - Black, Stephen Matthew

AU - Fineman, Jeffrey R.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - An increasing number of studies implicate oxidative stress in the development of endothelial dysfunction and the pathogenesis of cardiovascular disease. Further, this oxidative stress has been shown to be associated with alterations in both the endothelin-1 (ET-1) and nitric oxide (NO) signaling pathways such that bioavailable NO is decreased and ET-1 signaling is potentiated. However, recent data, from our groups and others, have shown that oxidative stress, ET-1, and NO are co-regulated in a complex fashion that appears to be dependent on the cellular levels of each species. Thus, when ROS levels are transiently elevated, NO signaling is potentiated through transcriptional, post-transcriptional, and post-translational mechanisms. However, in pediatric pulmonary hypertensive disorders, when reactive oxygen species (ROS) increases are sustained by ET-1 mediated activation of smooth muscle cell ETA subtype receptors, NOS gene expression and NO signaling are reduced. Further, increases in oxidative stress can stimulate both the expression of the ET-1 gene and the secretion of the ET-1 peptide. Finally, the addition of exogenous NO, and increasingly utilized therapy for pulmonary hypertension, can also lead to increases ROS generation via the activation of ROS generating enzymes and through the induction of mitochondrial dysfunction. Thus, this manuscript will review the available data regarding the interaction of oxidative and nitrosative stress, endothelial dysfunction, and its role in the pathophysiology of pediatric pulmonary hypertension. In addition, we will suggest avenues of both basic and clinical research that will be important to develop novel pulmonary hypertension treatment and prevention strategies, and resolve some of the remaining clinical issues regarding the use of NO augmentation.

AB - An increasing number of studies implicate oxidative stress in the development of endothelial dysfunction and the pathogenesis of cardiovascular disease. Further, this oxidative stress has been shown to be associated with alterations in both the endothelin-1 (ET-1) and nitric oxide (NO) signaling pathways such that bioavailable NO is decreased and ET-1 signaling is potentiated. However, recent data, from our groups and others, have shown that oxidative stress, ET-1, and NO are co-regulated in a complex fashion that appears to be dependent on the cellular levels of each species. Thus, when ROS levels are transiently elevated, NO signaling is potentiated through transcriptional, post-transcriptional, and post-translational mechanisms. However, in pediatric pulmonary hypertensive disorders, when reactive oxygen species (ROS) increases are sustained by ET-1 mediated activation of smooth muscle cell ETA subtype receptors, NOS gene expression and NO signaling are reduced. Further, increases in oxidative stress can stimulate both the expression of the ET-1 gene and the secretion of the ET-1 peptide. Finally, the addition of exogenous NO, and increasingly utilized therapy for pulmonary hypertension, can also lead to increases ROS generation via the activation of ROS generating enzymes and through the induction of mitochondrial dysfunction. Thus, this manuscript will review the available data regarding the interaction of oxidative and nitrosative stress, endothelial dysfunction, and its role in the pathophysiology of pediatric pulmonary hypertension. In addition, we will suggest avenues of both basic and clinical research that will be important to develop novel pulmonary hypertension treatment and prevention strategies, and resolve some of the remaining clinical issues regarding the use of NO augmentation.

KW - Cell signaling

KW - Gene expression

KW - Nitrosylation

KW - Pulmonary hypertension

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=33751086463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751086463&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2006.08.005

DO - 10.1016/j.vph.2006.08.005

M3 - Article

C2 - 17049313

AN - SCOPUS:33751086463

VL - 45

SP - 308

EP - 316

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 5

ER -